THE MIZEUR GROUP, LLC for CLENE NANOMEDICINE
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Aug 13, 2024 | $10,000 | Replaced |
| 2nd Quarter - Amendment | Sep 19, 2024 | $10,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
Clarifying the discrepancy between statute and FDA regulations regarding use of survivability as a clinical endpoint in the accelerated approval process; Urging FDA alignment between CBER and CDER on regulatory flexibility; and encouraging ability for thorough public review of promising treatments for ALS and other neurodegenerative diseases.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HEATHER R MIZEUR | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.